MELBOURNE, Australia — Eddie Osei-Nketia, who is New Zealand’s record holder in the 100 and 200 meters, completed his eligibility switch to Australia on Thursday.
The 24-year-old USC sprinter told The Associated Press he wants to help Australia…
Author: admin
-
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent’s next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).
Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, “IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward.”
Under the agreement:
- Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
- Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.
- Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China.
Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).
Detailed information about the collaboration can be found at the official website of Innovent Biologics.
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
SOURCE Innovent Biologics
Continue Reading
-
AI smartphone from ByteDance, ZTE debuts in China to strong sales
TechnologyDoubao voice assistant can help shop, plan trips
ByteDance’s Doubao AI assistant in the Nubia M153 phone can shop for users. (Photo by Itsuro Fujino)
ITSURO FUJINO
December 5, 2025 08:37 JST
GUANGZHOU — A new smartphone equipped with…
Continue Reading
-
Cochran-Siegle Second at Stifel Birds of Prey – U.S. Ski & Snowboard
- Cochran-Siegle Second at Stifel Birds of Prey U.S. Ski & Snowboard
- Odermatt dominates Beaver Creek World Cup downhill The Express Tribune
- US World Cup Downhill Skiing couriernews.com
- FIS Alpine Ski World Cup 2025/26: Marco Odermatt claims first…
Continue Reading
-
‘It’s good this final came to be’ – Lionel Messi welcomes Thomas Muller showdown as Inter Miami prepare for MLS Cup final against the Vancouver Whitecaps
Messi said he was pleased Muller had joined MLS and that the German’s presence raises the profile and competitive level of the final. He noted Miami and Vancouver know each other well after recent meetings and acknowledged Vancouver’s…
Continue Reading
-
‘It’s good this final came to be’ – Lionel Messi welcomes Thomas Muller showdown as Inter Miami prepare for MLS Cup final against the Vancouver Whitecaps
Messi said he was pleased Muller had joined MLS and that the German’s presence raises the profile and competitive level of the final. He noted Miami and Vancouver know each other well after recent meetings and acknowledged Vancouver’s…
Continue Reading
-
Warriors-Sixers, Lakers-Raptors: Live updates
Anthony Edwards, who dropped a season-high 44 points on Tuesday, and the Timberwolves go for consecutive wins over the Pelicans in New Orleans.
Enjoy the best of Thursday’s 5-game night with the NBA.com live blog, featuring all of the…
Continue Reading
-
Trump Wants to Trade Fuel Economy for Cheaper Cars. But It Might Not Work
The Trump administration says its proposal to roll back vehicle fuel economy standards, announced officially in the Oval Office on Wednesday, is an attempt to shave dollars off the ballooning cost of new cars in the US.
But the intended price drops likely won’t show up on dealership lots and showroom floors for months if not years, given the length of automakers’ product planning schedule. It would also likely force Americans to pay more, long-term, at another place they tend to visit more frequently: the pump.
The proposal from the US Department of Transportation would require automakers to reach a fleet-wide average of 34.5 miles per gallon by model year 2031, down from the 50.4-miles-per-gallon benchmark set by the Biden administration. (The Biden-era rules called for a 49-miles-per-gallon average in 2026.) The department estimates the change could save US auto buyers around $1,000 per car, adding up to $109 billion over the next five years. New vehicles now cost more than $49,000 on average, according to Edmunds. The government will accept public comments on the proposal through mid-January. It could be finalized sometime next year.
The rollback is part of a larger federal about-face on not only auto policy, but the government’s attitude on climate change. The Biden administration took a carrot-and-stick approach to vehicles and their effect on the environment. Light-duty cars and trucks alone are responsible for some 15 percent of US greenhouse gas emissions, according to the US Environmental Protection Agency. The previous administration tried to boost electric vehicle adoption by using tax subsidies for consumers and manufacturers interested in building fuel-efficient vehicles and technologies, including batteries. It also introduced penalties for those unable or unwilling to meet stricter environmental standards. Automakers should be able to hit next decade’s goals by selling more electric vehicles, the government then reasoned.
But as consumers failed to take to EVs quite as quickly as once hoped, automakers complained the rules were too onerous. “We’ve been clear and consistent: The current [fuel economy] rules finalized under the previous administration are extremely challenging for automakers to achieve given the current marketplace for EVs,” wrote John Bozzella, the president and CEO of top auto trade organization the Alliance for Automotive Innovation, in a media statement on Wednesday.
The new proposal, though intended to make new cars more affordable, won’t be a quick fix for consumers looking for price relief, analysts and environmental advocates say. “The regulatory landscape remains stop-and-start,” said Jessica Caldwell, the head of insights at Edmunds, in a media statement. The last Trump administration rolled back fuel economy standards, too. What might the next president do? Meanwhile, the administration continues to waffle on auto tariffs, which have forced US and global automakers to think about not only where their vehicles are manufactured but also where parts and base materials are made, too. That complexity adds expenses to automaking.
Also pushing up costs for automakers: the challenge of developing new technology like automated vehicle features and figuring out how to keep selling gas-powered vehicles to Americans while drivers in other countries take the leap to EVs. “Easing these requirements helps at the margins,” says Caldwell, “but it is unlikely to dramatically alter the broader commitments [automakers] have already made.”
The move, if finalized, could be better news for gas companies. “Weakening fuel economy standards won’t do much to make cars more affordable but is certain to make Americans buy a lot more gasoline,” says Albert Gore, the executive director of the Zero Emission Transportation Association, a group that represents companies up and down the electric vehicle supply chain.
Continue Reading
-
Apple loses AI chief, general counsel, policy VP and design head
Apple said Monday that its head of artificial intelligence is stepping down, with a veteran engineer from Google and Microsoft set to take over the division.
Apple’s General Counsel Kate Adams and Policy chief Lisa Jackson, who both… Continue Reading
